Telix Pharmaceuticals Limited
TLXNASDAQHealthcare● Active
$9.38
+$0.08(+0.86%)
Market Cap$3.2B
P/E Ratio—
52W High$18.49
52W Low$6.28
Telix Pharmaceuticals Limited (TLX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
TLX · earnings · updated Jun 8, 2026
Latest Earnings
Q1 FY2026Report Date: Feb 19, 2026EPS Actual
-$0.01
Est. $0.03 · -135.4%
Revenue
$0.41B
Est. $0.42B · -1.2%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Feb 19, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
TLX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 20, 2026 | $0.02 | — | — | — | $0.39B | — |
| ▼ Q1 FY2026 | Feb 19, 2026 | $0.03 | -$0.01 | -135.4% | $0.41B | $0.42B | -1.2% |
| ▼ Q3 FY2025 | Aug 20, 2025 | $0.13 | -$0.01 | -105.1% | $0.39B | $0.32B | +20.4% |
| ▼ Q1 FY2025 | Feb 20, 2025 | $0.09 | $0.07 | -25.2% | $0.37B | $0.14B | +172.3% |
| ▼ Q3 FY2024 | Aug 22, 2024 | $0.09 | $0.02 | -75.0% | $0.13B | $0.24B | -47.0% |
| — Q4 FY2023 | Dec 31, 2023 | — | $0.04 | — | $0.19B | $0.11B | +70.3% |
| ▼ Q2 FY2023 | Jun 30, 2023 | $0.04 | -$0.03 | -179.9% | $0.15B | $0.15B | -0.2% |
| ▼ Q4 FY2022 | Dec 31, 2022 | -$0.05 | -$0.07 | -45.5% | $0.09B | $0.09B | +6.9% |
Q3 FY2026
Aug 20, 2026
EPS Actual
—
EPS Est.
$0.02
EPS Surpr.
—
Revenue
—
Q1 FY2026
Feb 19, 2026Miss
EPS Actual
-$0.01
EPS Est.
$0.03
EPS Surpr.
-135.4%
Revenue
$0.41B
Q3 FY2025
Aug 20, 2025Miss
EPS Actual
-$0.01
EPS Est.
$0.13
EPS Surpr.
-105.1%
Revenue
$0.39B
Q1 FY2025
Feb 20, 2025Miss
EPS Actual
$0.07
EPS Est.
$0.09
EPS Surpr.
-25.2%
Revenue
$0.37B
Q3 FY2024
Aug 22, 2024Miss
EPS Actual
$0.02
EPS Est.
$0.09
EPS Surpr.
-75.0%
Revenue
$0.13B
Q4 FY2023
Dec 31, 2023
EPS Actual
$0.04
EPS Est.
—
EPS Surpr.
—
Revenue
$0.19B
Q2 FY2023
Jun 30, 2023Miss
EPS Actual
-$0.03
EPS Est.
$0.04
EPS Surpr.
-179.9%
Revenue
$0.15B
Q4 FY2022
Dec 31, 2022Miss
EPS Actual
-$0.07
EPS Est.
-$0.05
EPS Surpr.
-45.5%
Revenue
$0.09B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2030 | $0.33 | $0.33 | $0.34 | 1 |
| Q2 FY2030 | $0.26 | $0.26 | $0.26 | 1 |
| Q1 FY2030 | $0.41 | $0.41 | $0.41 | 1 |
| Q4 FY2029 | $0.34 | $0.34 | $0.34 | 1 |
| Q3 FY2029 | $0.22 | $0.22 | $0.22 | 1 |
| Q2 FY2029 | $0.04 | $0.04 | $0.04 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2030 | $10.8B | $10.9B | $11.0B | 1 |
| Q2 FY2030 | $8.1B | $8.2B | $8.3B | 1 |
| Q1 FY2030 | $1.1B | $1.1B | $1.1B | 1 |
| Q4 FY2029 | $1.1B | $1.1B | $1.1B | 1 |
| Q3 FY2029 | $0.8B | $0.9B | $0.9B | 1 |
| Q2 FY2029 | $0.8B | $0.8B | $0.8B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2026 | Feb 19, 2026 | -135.4% | $6.41 | $6.71 | +4.68% |
| ▼ Q3 FY2025 | Aug 20, 2025 | -105.1% | $11.30 | $10.97 | -2.92% |
| ▼ Q1 FY2025 | Feb 20, 2025 | -25.2% | $17.19 | $17.41 | +1.28% |
| ▼ Q3 FY2024 | Aug 22, 2024 | -75.0% | No price data | $15.15 | — |
| — Q4 FY2023 | Dec 31, 2023 | — | No price data | $15.15 | — |
| ▼ Q2 FY2023 | Jun 30, 2023 | -179.9% | No price data | $15.15 | — |
| ▼ Q4 FY2022 | Dec 31, 2022 | -45.5% | No price data | $15.15 | — |
| ▼ Q2 FY2022 | Jun 30, 2022 | -92.7% | No price data | $15.15 | — |
Q1 FY2026+4.68%
Report Date
Feb 19, 2026
EPS Beat/Miss
-135.4%
Price Before
$6.41
Price After
$6.71
Q3 FY2025-2.92%
Report Date
Aug 20, 2025
EPS Beat/Miss
-105.1%
Price Before
$11.30
Price After
$10.97
Q1 FY2025+1.28%
Report Date
Feb 20, 2025
EPS Beat/Miss
-25.2%
Price Before
$17.19
Price After
$17.41
Q3 FY2024—
Report Date
Aug 22, 2024
EPS Beat/Miss
-75.0%
Price Before
—
Price After
$15.15
Q4 FY2023—
Report Date
Dec 31, 2023
EPS Beat/Miss
—
Price Before
—
Price After
$15.15
Q2 FY2023—
Report Date
Jun 30, 2023
EPS Beat/Miss
-179.9%
Price Before
—
Price After
$15.15
Q4 FY2022—
Report Date
Dec 31, 2022
EPS Beat/Miss
-45.5%
Price Before
—
Price After
$15.15
Q2 FY2022—
Report Date
Jun 30, 2022
EPS Beat/Miss
-92.7%
Price Before
—
Price After
$15.15
Avg Miss Reaction+1.01%
Beat Rate0 / 8 quarters
Largest Move+4.68% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: TLX ends December
Telix Pharmaceuticals Limited (TLX) most recently reported earnings on February 19, 2026 for Q1 FY2026, posting EPS of $-0.01 — missing the analyst consensus of $0.03 by -135.4%. The next TLX earnings date is expected around September 1, 2026.
Each quarter, investors track TLX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. TLX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
TLX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
TLX earnings · 5 questionsTelix Pharmaceuticals Limited's next earnings report is expected around September 1, 2026. TLX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; TLX historically reports after market close (AMC).
TLX earnings datewhen is TLX earningsTLX next earnings datewhen does TLX report earningsTLX earnings calendar
▸ Source: FMP · Telix Pharmaceuticals Limited SEC filings · US GAAP · Telix Pharmaceuticals Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026